FZ-AD005
Based on 1 Customer Validation
FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The Kd value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer.
For research use only. We do not sell to patients.
- Purity : 97.04%
- Molecular Weight:154128 (average)
-
Storage:
-80°C, protect from light
All Topoisomerase Isoforms
More
Biological Activity
Description
IC50 & Target
|
Topoisomerase I |
In Vitro
FZ-AD005 (1 μg/mL; 144 hours) exhibits a strong bystander killing effect, eliminating both DLL3-positive NCI-H82 cells and DLL3-negative Ramos cells in a Transwell coculture system[1].
FZ-AD005 (0.78-100 nmol/L human DLL3) exhibits high affinity binding to human DLL3 (Kd=58.3 pmol/L) and FcRn (Kd=29 nmol/L), but very low affinity for FcγRI, FcγRIIa, and FcγIIIa, when tested in a biolayer interferometry assay[1].
FZ-AD005 (100 μg/mL; 7 days) is highly stable in human plasma, with only ~0.7% DXd released after 7 days of incubation at 37°C[1].
FZ-AD005 (200 pmol; 48 hours) rapidly internalizes into DLL3-expressing cells within 30 minutes, traffics to lysosomes, and releases DXd in a time-dependent manner when tested over 48 hours[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:DLL3-positive NCI-H82 cells, DLL3-negative Ramos cells
-
Concentration:1 μg/mL
-
Incubation Time:144 hours
-
Result:Effectively eliminated both NCI-H82 and Ramos cell populations in the coculture system.
Parmacokinetics
In Vivo
Single intravenous administration of FZ-AD005 (1.5-6 mg/kg; intravenous injection; single dose) at doses of 1.5, 3 and 6 mg/kg induces complete tumor growth inhibition in male NOD/SCID mice inoculated with NCI-H660 NEPC xenografts[1].
FZ-AD005 (1-5 mg/kg; intravenous injection; once weekly; 2 total administrations) induces significant tumor growth inhibition in female BALB/c nude mice bearing NCI-H82 SCLC xenografts; at intravenous doses of 1, 3 and 5 mg/kg given once weekly for 2 total administrations, its TGI ranges from 76.52% to 97.13%[1].
FZ-AD005 (1.5-6 mg/kg; intravenous injection; single administration) induces potent to complete tumor growth inhibition in mice bearing SCLC LU-5236 PDX, with TGIs ranging from 98.51% to 100.00% across different dose groups on day 21 post-administration[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID (female) with Small cell lung cancer[1]
-
Dosage:2.5 mg/kg; 5 mg/kg; 10 mg/kg
-
Administration:i.v.; single dose
-
Result:Achieved tumor growth inhibition (TGI) values of 86.21% (2.5 mg/kg), 94.53% (5 mg/kg), and 95.54% (10 mg/kg) compared to vehicle control.
Caused no obvious body weight loss in treated mice.
-
Animal Model:NOD/SCID (male) with Neuroendocrine prostate cancer[1]
-
Dosage:1.5 mg/kg; 3 mg/kg; 6 mg/kg
-
Administration:i.v.; single dose
-
Result:Exhibited complete tumor growth inhibition in all dose groups compared to vehicle control.
Caused no obvious body weight loss in treated mice.
-
Animal Model:BALB/c nude (female) with Small cell lung cancer[1]
-
Dosage:1 mg/kg; 3 mg/kg; 5 mg/kg
-
Administration:i.v.; weekly; 2 total doses
-
Result:Achieved tumor growth inhibition (TGI) values of 76.52% (1 mg/kg), 94.19% (3 mg/kg), and 97.13% (5 mg/kg) compared to vehicle control.
Demonstrated notably superior efficacy to lurbinectedin (23.48% TGI at 0.18 mg/kg).
Caused no obvious body weight loss in treated mice.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 154128 (average)
-
Color Colorless to light yellow
-
SMILES
[FZ-AD005]
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)